DrugPatentWatch Database Preview
Patent: 9,335,320
» See Plans and Pricing
Summary for Patent: 9,335,320
| Title: | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies |
| Abstract: | Combinations of PI3K inhibitor compounds having Formula I and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hematopoietic malignancies. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed ##STR00001## |
| Inventor(s): | Ebens, Jr.; Allen J. (San Carlos, CA), Friedman; Lori (San Carlos, CA) |
| Assignee: | Genentech, Inc. (South San Francisco, CA) |
| Application Number: | 13/968,202 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,335,320
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 002 | 2017-06-22 | Start Trial | Genentech, Inc. (South San Francisco, CA) | 2039-02-26 | RX | Orphan | search |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | Genentech, Inc. (South San Francisco, CA) | 2039-02-26 | RX | Orphan | search |
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 002 | 1997-11-26 | Start Trial | Genentech, Inc. (South San Francisco, CA) | 2039-02-26 | RX | search | |
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 001 | 1997-11-26 | Start Trial | Genentech, Inc. (South San Francisco, CA) | 2039-02-26 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 9,335,320
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2010105008 | Start Trial |
| United States of America | 2010233164 | Start Trial |
| United States of America | 2013330765 | Start Trial |
| United States of America | 8536161 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
